Andrea Fava

And Ioannis Parodis presented several data on molecular signatures in SLE and prediction of response to some drugs, which was quite interesting.

Andrea Fava talked on urinary biomarkers and the future of lupus nephritis monitoring.

And Thomas Dorner presented us, what do we mean when we are talking about immune reset? So Zair, from the clinician point of view, this plenary was a tough one.

What do you think we learned and what can we bring to the clinical practice right now from this plenary?

course.

Because the lupus feed is evolving every day and the science is more and more important for the management of lupus, of SLE.

And I would like to highlight the presentation given by Andrea Fava that you said about what are the... urinary biomarkers that we can use instead of doing a kidney biopsy.

We are not at the end of the day, but we have promising results about some urinary biomarkers that can be measured, assessed, and for which maybe in the future we can develop what we call the liquid biopsy.